Abstract:Background and Objective: Immune checkpoint inhibitors (ICI) were a major clinical advancement that provided an opportunity to improve the prognosis of patients with non-small cell lung cancer (NSCLC). However, programmed death-ligand-1 (PD-L1) expression does not sufficiently predict ICI efficacy in NSCLC patients. In recent studies, the tumor immune microenvironment (TIME) was shown to have a central role in lung cancer progression and to affect clinical outcome of patients diagnosed with lung cancer. As development of new therapeutic targets to overcome ICI resistance is a priority, understanding the TIME is important. Recently, a series of studies was conducted to target each component of TIME to improve efficacy of cancer treatment. In this review, important features related to TIME, its heterogeneity and current trends in treatment targeting the component of TIME are discussed.Methods: PubMed and PMC were searched from January 1st, 2012 to August 16th, 2022 using the following key words: "NSCLC", "Tumor microenvironment", "Immune", "Metastasis" and "Heterogeneity".Key Content and Findings: Heterogeneity in the TIME can be either spatial or temporal. Subsequent to heterogeneous changes in the TIME, treatment of lung cancer can be more challenging because drug resistance is more likely to occur. In terms of the TIME, the main concept for increasing the chance of successful NSCLC treatment is to activate immune responses against tumor cells and inhibit immunosuppressive activities. In addition, relevant research is focused on normalizing an otherwise aberrant TIME in NSCLC patients. Potential therapeutic targets include immune cells, cytokine interactions, and non-immune cells such as fibroblasts or vessels.Conclusions: In management of lung cancer, understanding TIME and its heterogeneity is significant to treatment outcomes. Ongoing trials including various treatment modalities such as radiotherapy, cytotoxic chemotherapy, and anti-angiogenic treatment and regimens inhibiting other immunoinhibitory molecules are promising.

Heterogeneity of the tumor immune microenvironment and clinical interventions

Heterogeneity of the tumor immune microenvironment and its clinical relevance

Heterogeneity in Primary Tumors and Corresponding Metastases: Could It Provide Us with Any Hints to Personalize Cancer Therapy?

Advancements in technology for characterizing the tumor immune microenvironment

Understanding the tumor immune microenvironment (TIME) for effective therapy

Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy

Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

From complexity to clarity: unravelling tumor heterogeneity through the lens of tumor microenvironment for innovative cancer therapy

A narrative review of tumor heterogeneity and challenges to tumor drug therapy

The heterogeneity of tumour immune microenvironment revealing the CRABP2/CD69 signature discriminates distinct clinical outcomes in breast cancer

Immunotherapy: Reshape the Tumor Immune Microenvironment

Liver tumour immune microenvironment subtypes and neutrophil heterogeneity

Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond

Role of the tumor immune microenvironment in tumor immunotherapy

Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance

Tumor Microenvironment Heterogeneity: Challenges and Opportunities

Unravelling immune microenvironment features underlying tumor progression in the single-cell era

Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer

Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance